Gerresheimer Glas, a subsidiary of Gerresheimer, has entered into a purchase agreement to acquire Blitz LuxCo, the holding company of Bormioli Pharma.  

The acquisition is valued at approximately €800m ($866.14m).  

Bormioli Pharma, with nine production sites across Europe, offers a range of pharmaceutical primary packaging products made from glass and plastic, including closure solutions, accessories, and dispensing systems.  

The acquisition is poised to create a robust Moulded Glass business unit, which is projected to generate sales of about €750m in 2024, with an earnings before interest, taxes, depreciation, and amortisation (EBITDA) margin of roughly 21% before synergies.  

Gerresheimer expects the acquisition to strengthen its European presence, particularly in Southern Europe and also cement its position as a full-service provider for the pharmaceutical and biotech sectors. 

The acquisition aligns with Gerresheimer’s ‘formula g’ corporate strategy.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Financially, the acquisition is expected to increase Gerresheimer’s adjusted EBITDA margin by 50 to 100 basis points in the short term and enhance its earnings per share by more than 10% from the first year post-closing.  

The transaction is subject to standard closing conditions and approvals, with completion anticipated in the fourth quarter (Q4) of the 2024 financial year. 

Gerresheimer CEO Dietmar Siemssen said: “With this transaction, we are putting an exclamation mark on our growth ambitions. Bormioli Pharma is an ideal strategic fit for us and accelerates our transformation into an integrated systems and solutions provider.  

“In particular, we are expanding our portfolio to include further high-value solutions. Both companies complement each other both in terms of product portfolio and regional coverage with production sites in Europe.” 

The purchase will be financed through a bridge loan provided by a banking syndicate comprising UniCredit, Commerzbank, and LBBW, with advisory support from Triton.